An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer
- PMID: 37191665
- DOI: 10.1158/1078-0432.CCR-23-0652
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer
Abstract
PARP inhibitors exploit synthetic lethality in homologous recombination-deficient (HDR) cells and are standard-of-care treatment in newly diagnosed and relapsed epithelial ovarian cancer (EOC). A recent article demonstrated that a second course of olaparib can be safely administered to women with BRCA-mutated EOC. See related article by Morgan et al., p. 2602.
©2023 American Association for Cancer Research.
Comment in
-
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.Clin Cancer Res. 2023 Jul 14;29(14):2602-2611. doi: 10.1158/1078-0432.CCR-22-3282. Clin Cancer Res. 2023. PMID: 36799931
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous